Semax Research Guide (2026): Nootropic Peptide Sourcing & Quality

Semax sits in an unusual corner of the peptide research world. Unlike BPC-157 or the GLP-1 analogs that dominate North American supplier catalogs, Semax came out of Soviet-era pharmacology and remains better known in Russian clinical literature than in Western research circles. For laboratories working on cognitive, neuroprotective, or stroke-model studies, finding a clean source of this Russian nootropic is half the battle.

This guide covers what Semax is, what the published research literature has examined, how it compares to its sister compound Selank, and what to look for when sourcing it for in vitro and animal research.

What Semax Is

Semax is a synthetic heptapeptide (7 amino acids) with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the late 1980s as a synthetic analog of adrenocorticotropic hormone fragment ACTH(4-10).

The structural trick: by removing the hormonally active portion of ACTH and adding a Pro-Gly-Pro tail to the C-terminus, the researchers produced a peptide that retains the central nervous system activity of ACTH fragments while eliminating the hormonal effects on the adrenal axis. The Pro-Gly-Pro tail also confers resistance to enzymatic degradation, which is why Semax has a meaningful half-life despite being a short peptide.

Semax is registered as a medication in Russia and Ukraine for ischemic stroke and certain cognitive indications. It is not FDA-approved in the United States and is sold strictly as a research peptide in Western markets.

The Science: Heptapeptide Structure and Mechanism

The full sequence breakdown:

Position	Amino acid	Role
1	Methionine (Met)	N-terminus
2	Glutamic acid (Glu)	ACTH(4-10) backbone
3	Histidine (His)	ACTH(4-10) backbone
4	Phenylalanine (Phe)	ACTH(4-10) backbone
5	Proline (Pro)	Synthetic stabilizer
6	Glycine (Gly)	Synthetic stabilizer
7	Proline (Pro)	C-terminus, enzyme resistance

The first four residues mirror the ACTH(4-7) sequence that carries the neurotropic activity of the parent hormone. The Pro-Gly-Pro extension is the Russian research group's key contribution — it dramatically slows proteolytic breakdown compared to native ACTH fragments, which are cleared in minutes.

Mechanistically, published Russian research has examined several pathways: modulation of brain-derived neurotrophic factor (BDNF) expression, effects on the dopaminergic and serotonergic systems, and influence on the hypothalamic-pituitary axis without direct cortisol stimulation. The compound has been studied for crossing the blood-brain barrier when administered intranasally, which is the dominant route in the published literature.

What Research Has Examined

Semax has been studied across several preclinical and clinical research areas in Russian and, more recently, international literature.

Nootropic and cognitive research. Animal models have examined memory retention, attention, and learning behavior in rodents administered Semax. The Institute of Molecular Genetics group and collaborators have published on hippocampal gene expression changes, with several studies looking at BDNF and NGF (nerve growth factor) modulation.

Neuroprotective research. Stroke and ischemia models in rodents have been a major focus. Russian clinical literature describes use in patients with acute ischemic stroke, with the peptide administered intranasally in the hours and days following the event. Western researchers should treat this as research literature, not clinical practice.

Optic nerve and ophthalmic research. A smaller body of work has looked at Semax in optic nerve injury and retinal models, including studies on glaucoma-related research.

ADHD and developmental research. Russian pediatric literature includes work on Semax in attention-deficit research, though these studies are difficult to access in English and have not been replicated in Western trials.

The compound is not approved by the FDA, EMA, or other Western regulators. It does not appear in standard Western nootropic guidelines because the supporting literature is concentrated in Russian journals and the regulatory pathway differs substantially.

Semax vs Selank: The Sister Peptides

Researchers new to the Russian neuropeptide family often confuse Semax and Selank. They come from the same lab, use the same Pro-Gly-Pro stabilizing strategy, and are both 7-amino-acid sequences. They study different research areas.

Feature	Semax	Selank
Sequence	Met-Glu-His-Phe-Pro-Gly-Pro	Thr-Lys-Pro-Arg-Pro-Gly-Pro
Parent compound	ACTH(4-10) fragment	Tuftsin fragment
Primary research area	Nootropic, neuroprotective	Anxiolytic, immunomodulatory
Route in research	Intranasal	Intranasal
Developer	Institute of Molecular Genetics (Russia)	Institute of Molecular Genetics (Russia)
Russian medical status	Registered for stroke, cognitive indications	Registered for anxiety disorders
FDA status	Not approved, research use only	Not approved, research use only

Both peptides share the Pro-Gly-Pro tail and intranasal route, but their parent compounds and research targets are distinct. A lab interested in stress and anxiety models would look at Selank; a lab interested in cognitive and stroke models would look at Semax. Some research groups examine them together as part of the broader Russian neuropeptide family.

The Sourcing Landscape

Semax sourcing is meaningfully different from BPC-157 or GLP-1 sourcing. Three patterns dominate:

1. Russian pharmacy product (not research grade). The branded pharmaceutical Semax nasal drops sold in Russian pharmacies are formulated for human use under Russian regulation. These are not research peptides, are not legal to import into most Western countries without prescription channels, and are not appropriate for laboratory research because the formulation, excipients, and labeling are pharmaceutical rather than research-grade.

2. Generic Chinese API. A significant portion of Semax sold as a research peptide in the West originates from Chinese custom peptide synthesis houses. Quality varies enormously. Without a third-party COA from an independent lab, a buyer has no way to verify identity, purity, or whether the product is the correct Semax sequence rather than a related ACTH fragment.

3. Western research suppliers with documentation. A smaller group of Western suppliers stock Semax as a research peptide alongside Selank, often with third-party HPLC and mass spectrometry COAs. This is the appropriate channel for laboratory research.

The niche status of Semax means many large peptide suppliers do not carry it at all. It tends to show up at suppliers that specifically stock nootropic and neuropeptide research compounds rather than the general peptide catalog.

Quality Markers for Semax

When evaluating a Semax supplier for research, the diligence checklist is similar to other research peptides but with specific notes for this compound.

Third-party COA on the specific lot. The COA should be from an independent lab — Janoshik Analytical and MZ Biolabs are the two most commonly referenced in the research peptide market — not from the supplier's own bench. Lot-specific is non-negotiable.

Mass spectrometry confirming the heptapeptide mass. The theoretical monoisotopic mass of Semax (free base) is approximately 813.4 Da. The COA should show a mass spec peak matching this within instrument tolerance. A mismatch suggests either a different sequence or significant impurity.

HPLC purity above 98%. Reputable research-grade Semax typically reports 98% or higher purity by reversed-phase HPLC. Anything below 95% should be questioned for research applications where downstream assays are sensitive to impurities.

Sequence verification. Some suppliers provide amino acid analysis or sequencing data in addition to HPLC. For a compound that can be confused with related ACTH analogs, sequence-level confirmation is valuable.

Endotoxin testing for relevant applications. If the research involves cell culture or animal injection rather than purely chemical work, endotoxin (LAL) testing matters. Not every supplier provides it.

Storage and shipping. Semax should ship lyophilized and be stored at -20°C or colder for long-term stability. Suppliers that ship without temperature consideration or sell reconstituted material are a red flag.

Administration in Research Models

The published Semax literature is dominated by intranasal administration. The rationale: the peptide crosses the nasal mucosa and reaches the central nervous system relatively efficiently in rodent and primate models, and this matches the registered clinical formulation in Russia.

For research purposes, intranasal dosing in animal models typically uses microliter volumes delivered to each nostril with a fine pipette. Subcutaneous and intraperitoneal routes have also been examined in the literature but with different pharmacokinetic profiles.

Reconstitution for research follows the standard peptide approach: bacteriostatic water or sterile saline depending on the assay, with the lyophilized powder dissolved gently and stored at refrigerator temperature once reconstituted, with a typical reconstituted shelf life of two to four weeks.

This guide is research-focused. Nothing in this section should be read as guidance for human use.

Pricing

Semax pricing reflects its niche status. It is more expensive per milligram than commodity peptides like BPC-157 because of lower production volumes and a smaller supplier pool.

Quantity	Typical Western research supplier range
5 mg vial	$35 – $55
10 mg vial	$55 – $85
30 mg (bulk)	$130 – $180

Suppliers selling Semax for substantially below these ranges should be evaluated carefully — at the low end of the market, the risk of identity or purity issues rises. Suppliers selling for substantially above these ranges should be asked what justifies the premium (typically additional analytical documentation or specific quality systems).

Pricing tends to track Selank closely, since the same supplier base usually carries both.

Bottom Line

Semax is a legitimately interesting research peptide with a substantial Russian literature base and a small but real Western research footprint. For laboratories working in cognitive, neuroprotective, or stroke models — or for researchers studying the broader Russian neuropeptide family alongside Selank — sourcing is the practical bottleneck.

The compound's niche status means fewer suppliers carry it, which is actually helpful: the field self-selects for suppliers who specialize in nootropic and neuropeptide research compounds rather than general catalogs. The diligence checklist is the same as any research peptide — third-party COA, mass spec confirming the heptapeptide, HPLC purity above 98%, lot-specific documentation — with extra attention to sequence verification given the ACTH-analog family.

Avoid the Russian pharmacy product as a research source, treat unverified Chinese API with caution, and work with Western research suppliers who carry Semax alongside other neuropeptide research compounds and publish independent analytical documentation.

2026 Evaluation

9.6/10

Top-Ranked 2026 Supplier

The top-ranked supplier in our 2026 evaluation

ROEHN Research tested at 99.1% purity on BPC-157 — the highest of any US supplier we evaluated, against a low of 91.3%. Readers save 15% on a first order with code FREE15.

View ROEHN Research→

Save 15% with code FREE15

• Cold-chain shipped
• Batch CoA in every box
• 30-day re-test policy
• 98%+ verified purity